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Abstract 
Hypertension is a risk factor for the vascular permeability and neovascularization that 
threatens vision in diabetic retinopathy (DR). Excess reactive oxygen species derived from 
the NADPH oxidase (Nox) isoforms, Nox1 and Nox4, contributes to vasculopathy in DR, 
however, if Nox1/4 inhibition is beneficial in hypertensive DR is unknown. Here, we 
determined that diabetic spontaneously hypertensive rats (SHR) had exacerbated retinal 
vascular permeability and expression of angiogenic and inflammatory factors, compared to 
normotensive diabetic Wistar Kyoto rats (WKY). GKT136901, a specific dual inhibitor of 
Nox1 and Nox4, prevented these events in diabetic WKY and SHR. Retinal 
neovascularization does not develop in diabetic rodents and therefore the oxygen-induced 
retinopathy (OIR) model is used to evaluate this pathology. We previously demonstrated that 
Nox1/4 inhibition reduced retinal neovascularization in OIR. However, although Nox5 is 
expressed in human retina, its contribution to retinopathy has not been studied in vivo, largely 
due to its absence from the rodent genome. We generated transgenic mice with inducible 
human Nox5 expressed in endothelial cells (Ve-CAD+Nox5+mice). In Ve-CAD+Nox5+ mice 
with OIR, retinal vascular permeability and neovascularization as well as the expression of 
angiogenic and inflammatory factors were increased compared to wild-type littermates. In 
bovine retinal endothelial cells which express Nox1, Nox4 and Nox5, Nox1/4 inhibition as 
well as Nox5 silencing RNA reduced the high glucose-induced up-regulation of oxidative 
stress, angiogenic and inflammatory factors. Collectively, these data indicate the potential of 
Nox1, Nox4 and Nox5 inhibition to reduce vision-threatening damage to the retinal 
vasculature. 
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Introduction 
Diabetic retinopathy (DR) is a leading cause of vision loss and blindness across the globe 
with approximately 93 million people estimated to have DR and 29 million people vision-
threatening DR.1 The clinical hallmark of DR is damage to the retinal vasculature 
characterized by vascular permeability and oedema due to breakdown of the blood-retinal 
barrier (BRB) as well as neovascularization.2 This vascular pathology is driven by a number 
of factors including vascular permeability and angiogenic agents such as vascular endothelial 
growth factor (VEGF), and pro-inflammatory molecules,2 as well as hypertension which is a 
risk factor for DR3, 4 and can damage the retina in the absence of diabetes.5 Agents to inhibit 
VEGF have revolutionised the treatment of DR,6 and anti-hypertensive therapies such as 
blockers of the angiotensin type 1 receptor have beneficial effects.5, 7 However, these 
approaches are not completely retinoprotective7 which has led to considerable interest in 
targeting other factors that have a causal role in DR. 
Oxidative stress, the excess production of reactive oxygen species (ROS), is a major 
contributor to diabetic complications including DR.8 Excess ROS promotes the production of 
angiogenic and inflammatory factors9, 10 that cause the increased vasculopathy and 
inflammation that develops in DR.11, 12 NADPH oxidase (Nox) is of interest as a treatment 
target for DR as this enzyme family’s sole function is the production of ROS.13 There are 
seven known Nox isoforms of which Nox1, Nox2 and Nox4 are implicated in the 
pathogenesis of vascular dysfunction and inflammation in various retinal diseases.14, 15 Of 
growing interest is the role of Nox5 in vascular disease as it is the only calcium-activated 
Nox isoform present in endothelium and it promotes endothelial cell proliferation16 and 
hypertension.17 Nox5 is expressed in human retina,15 but is not easily studied in vivo due to 
its absence from the mouse and rat genome, albeit Nox5 is expressed in other species such as 
cows and rabbits.18 
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Multiple pathways are involved in the increase in Nox and ROS levels that occur in 
hypertension and diabetes including the renin-angiotensin system, sheer stress on blood 
vessels, the hyperglycaemic-induction of metabolic pathways and inflammation.10 19, 20 21 
However, treatment strategies to block the excess production of ROS derived from Nox have 
until recently been hindered by the absence of agents that inhibit specific Nox isoforms.13 
GKT136901 and GKT137831 are two structurally related compounds that exhibit potent dual 
action inhibition of Nox1 and Nox4 and have beneficial effects in various pre-clinical models 
of disease.15, 22-24 We hypothesized that GKT136901 would have retinoprotective effects in 
hypertensive DR and therefore studied spontaneously hypertensive rats (SHR) with 
streptozotocin diabetes and made comparisons to normotensive Wistar Kyoto rats (WKY). 
Further, we reasoned that Nox5 would promote retinal neovascularization and thus studied 
endothelial specific Nox5 transgenic mice in the oxygen-induced retinopathy (OIR) model as 
well as primary cultures of bovine retinal endothelial cells (BREC) since cows express Nox5. 
 
Methods 
All methods are available within the article and online-only Data Supplement. The data that 
support the findings of this study are available from the corresponding author upon 
reasonable request.  
 
Results 
Body weight, blood glucose and blood pressure 
The results are summarised in Table S1 (online-only Data Supplement). Diabetes reduced 
body weight and increased blood glucose levels in WKY and SHR but had no effect on 
systolic blood pressure. GKT136901 had no effect on body weight, blood glucose and 
systolic blood pressure. Ve-Cad+Nox5+ mice had similar body weights (6.4±0.2g) as their 
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littermate controls (VE-Cad-Nox5+, 6.5±0.1g; VE-Cad+Nox5-, 6.9±0.1g; VE-Cad+Nox5+, 
6.8±0.2g). 
 
Nox expression in retina of hypertensive and diabetic rats 
The mRNA levels of Nox1, Nox2 and Nox4 in retina were increased in non-diabetic SHR 
compared to non-diabetic WKY (Figures 1A to 1C). Nox1, Nox2 and Nox4 mRNA were 
increased in diabetic WKY compared to non-diabetic WKY controls. In SHR, only Nox4 
mRNA levels were increased by diabetes compared to non-diabetic SHR (Figure 1C).  
 
Retinal oxidative stress is prevented by Nox1/4 inhibition in rats 
To evaluate oxidative stress, two complementary approaches were used. Firstly, 
immunohistochemistry was performed for 8-hydroxyguanine (8-OHdG) a major product of 
DNA oxidation and secondly, total superoxide levels were measured with the lucigenin 
assay. 8-OHdG immunolabeling was present at low levels in ganglion cells in non-diabetic 
WKY (Figures 1D and 1E). Hypertension augmented 8-OHdG immunolabeling in ganglion 
cells and it was also present in the inner nuclear layer (Figures 1D and 1E). Diabetes in WKY 
and SHR increased 8-OHdG in these sites. These findings are consistent with reports of 
increased ROS levels in ganglion cells which may contribute to neurodegeneration.25 
Immunolabeling was also present in the cell processes of macroglial Müller cells (Figures 1D 
and 1E). In diabetic WKY and SHR, GKT136901 reduced 8-OHdG immunolabeling to 
almost the level of respective non-diabetic controls (Figures 1D and 1E). Superoxide levels in 
retina were not increased in non-diabetic SHR but elevated in diabetic WKY and SHR and 
reduced to control levels with GKT136901 treatment (Figure 1F). 
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Retinal vascular permeability induced by diabetes is exacerbated in SHR and prevented 
by Nox1/4 inhibition 
Vascular permeability in DR is influenced by growth factors which promote impaired 
endothelial barrier function.26 Vascular leakage into the retina and vitreous cavity were 
increased by diabetes in WKY and further increased in SHR, with vascular leakage highest in 
diabetic SHR (Figures 2A and 2B). Nox1/4 inhibition prevented vascular leakage into both 
the retina and vitreous of WKY and SHR with diabetes (Figures 2A and 2B). 
VEGF and angiopoietin-2 are key retinal vascular permeability and angiogenic factors 
in DR.26 Diabetic WKY exhibited elevated levels of VEGF and angiopoietin-2 in retina as 
well as VEGF in vitreous compared to non-diabetic WKY (Figures 2C to 2F). In retina, 
VEGF mRNA and protein levels were further increased in diabetic SHR (Figures 2C and 
2E); however, angiopoietin-2 mRNA levels were similar in WKY and SHR with diabetes 
(Figure 2F). In diabetic WKY and SHR, GKT136901 prevented the increase in VEGF and 
angiopoietin-2 with levels similar to their respective non-diabetic controls (Figures 2C to 2F). 
An important component of impaired endothelial barrier function is the decreased 
expression of endothelial cell tight junctional proteins, zona occludin-1 (ZO-1) and 
occludin.27 Diabetes reduced the expression of ZO-1 and occludin in retina compared to non-
diabetic WKY (Figure S1, on-line Data Supplement). In retina of SHR, these junctional 
proteins were reduced compared to normotensive non-diabetic WKY, and further reduced 
with diabetes. Nox1/4 inhibition prevented the decrease in ZO-1 and occludin in the retinas 
of WKY and SHR with diabetes, although the protection afforded by GKT136901 was most 
striking in diabetic WKY for occludin (Figure S1, on-line Data Supplement).  
 
Diabetes-induced Müller cell gliosis and inflammation were increased in SHR and 
reduced by Nox1/4 inhibition 
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Reactive gliosis is indicative of BRB breakdown and features increased levels of glial 
fibrillary acidic protein (GFAP) in Müller cells and astrocytes.27 Immunolabeling for GFAP 
was minimal and largely on the retinal surface in non-diabetic WKY but increased and 
present in Müller cell and astrocyte processes in retinas from diabetic WKY (Figure 3A). 
GFAP immunolabeling was increased in non-diabetic SHR compared to non-diabetic WKY, 
with the highest expression in diabetic SHR. Nox1/4 inhibition reduced GFAP in WKY and 
SHR with diabetes to the level of WKY non-diabetic controls (Figure 3B). 
Inflammatory factors contribute to the development of DR.28 The mRNA levels of 
intracellular adhesion molecule-1 (ICAM-1) and tumour necrosis factor-α (TNFα) in the 
retina were increased in non-diabetic SHR compared to non-diabetic WKY (Figures 3C and 
3D). Diabetes increased these inflammatory factors in the retinas of both rat strains with the 
highest levels in diabetic SHR. GKT136901 prevented the diabetes-induced increase ICAM-1 
and TNFα in retinas of WKY and SHR (Figures 3C and 3D). The protein levels of monocyte 
chemotactic protein-1 (MCP-1) in retina and vitreous were increased by diabetes in both 
WKY and SHR (Figures 3E and 3F) and further increased by hypertension in diabetic SHR 
(Figure 3E). GKT136901 reduced MCP-1 protein levels in retina and vitreous of SHR and 
WKY with diabetes (Figures 3E and 3F). 
 
Nox1/4 inhibition reduced damage to retinal endothelial cells in vitro 
To further examine the effect of Nox1/4 inhibition on the retinal vasculature we studied 
primary cultures of BREC. The expression of Nox1 and Nox4, but not Nox2 were increased 
by 72 hours of high glucose (Figure 4A). As cows like humans express Nox5, we evaluated 
this Nox isoform and found increased mRNA levels following exposure to high glucose 
(Figure 4A). In BREC exposed to high glucose, ROS levels measured by dihydroethidium 
(DHE) flow cytometry, were increased compared to normal glucose controls, and reduced 
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with GKT136901 (Figure 4B). High glucose reduced ZO-1 protein levels, which were 
restored by GKT136901 (Figures 4C and 4D). ICAM-1, a marker of vascular inflammation, 
was increased by high glucose and reduced by GKT136901 (Figure 4E). 
 
Nox5 inhibition reduced high glucose-induced angiogenic and inflammatory factors in 
retinal endothelial cells in vitro.  
The increased expression of Nox5 in BREC following exposure to high glucose led us to 
investigate the effect of silencing Nox5 using small interfering RNAs (si-Nox5). In BREC, 
si-Nox5 reduced Nox5 protein levels by 40% and mRNA levels by 60% (Figure S2, online-
only Data Supplement), while the expression of Nox1, Nox2 and Nox4 were not affected by 
si-Nox5 compared to BREC treated with a scrambled siRNA (si-scr) (Figure S3, online-only 
Data Supplement). As GKT136901 inhibits Nox5, although with less efficiency than Nox1 
and Nox4,13 we evaluated if this compound influenced Nox5 expression in BREC. 
GKT136901 reduced the high glucose-induced increase in Nox5 mRNA (Figure S4, on-line 
Data Supplement). Next, we determined that ROS levels measured by DHE flow cytometry 
were increased in BREC exposed to high glucose and reduced with si-Nox5 (Figures 5A and 
5B). Furthermore, VEGF mRNA and protein levels (Figures 5C and 5D) as well as ICAM-1 
mRNA levels (Figure 5E) were elevated in BREC exposed to high glucose and reduced with 
si-Nox5. 
 
Nox5 exacerbated retinal oxidative stress and neovascularization in OIR 
With in vitro studies clearly demonstrating a key role for Nox5 in promoting oxidative stress 
and modulating glucose-induced expression of angiogenic and inflammatory factors the 
ability of Nox5 to influence retinal vascular disease in vivo was explored. Endothelial cell-
specific Nox5 transgenic (VE-Cad+Nox5+) mice were subjected to OIR, a model of retinal 
 9 
neovascularization. We first confirmed Nox5 expression in these transgenic mice by real-
time PCR. Nox5 mRNA was detected in the retinas of VE-Cad+Nox5+ mice (Ct numbers 31-
32, Figure S5A, online-only Data Supplement) while their littermate controls had 
undetectable levels of Nox5 mRNA as predicted since Nox5 is not present in the mouse 
genome. The ability of Nox5 to induce oxidative stress was confirmed by increased 
superoxide levels in the retinas of VE-Cad+Nox5+mice, while the levels of other Nox 
isoforms were unchanged compared to littermate controls (Figures S5B to S5E, online-only 
Data Supplement). Next, we examined if VE-Cad+Nox5+ mice had increased retinal 
vasculopathy. VE-Cad+Nox5+ mice with OIR had enhanced retinal neovascularization 
(Figures 6A and 6B) and vascular leakage (Figure 6C) compared to OIR controls. 
Furthermore, VEGF protein and mRNA levels were elevated (Figures 6D and 6E) as well as 
ICAM-1 levels (Figure 6F) in retina compared to OIR controls.  
 
Discussion 
To our knowledge this is the first study to identify that a specific dual inhibitor of Nox1/4 
prevents the vision-threatening damage to the retinal vasculature that occurs due to diabetes 
in the setting of concomitant hypertension. This is important since most subjects with vision 
threatening DR have systemic hypertension. In both normotensive WKY and hypertensive 
SHR with diabetes, the Nox inhibitor GKT136901 protected the BRB by reducing vascular 
permeability as well as VEGF levels within the retina and vitreous. These vasculo-protective 
actions were confirmed in vitro and in vivo, with GKT136901 preventing the diabetes-
induced decline in the endothelial cell tight junctional proteins, ZO-1 and occludin, which are 
critical for BRB integrity. Our findings are likely to be relevant to patients with hypertension 
and DR as both Nox1 and Nox4 are present in human retina.15 Nevertheless, we suggest that 
a potential causal role for Nox5 in retinal vasculopathy cannot be overlooked due to the 
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expression of this Nox isoform in human retina,15 and the ability of Nox5 to promote 
angiogenic responses in endothelial cells in vitro.16 Our in vivo and in vitro data strongly 
support this postulate as we present new evidence that overexpression of Nox5 in the 
endothelium exacerbates retinal neovascularization and vascular permeability. Furthermore, 
Nox5 siRNA ameliorates high glucose-mediated damage to retinal endothelial cells.  
Diabetes and hypertension can compromise the integrity of the BRB resulting in vision-
threatening vascular leakage,29 pathology linked to oxidative stress.12, 25, 30 Indeed, ROS 
levels increase in the rat retina a few weeks after the onset of diabetes preceding the 
development of retinal vasculopathy.31, 32 Our findings are in agreement since 8-OHdG 
immunolabeling increased in ganglion cells and macroglial Müller cells of SHR retina. 
Diabetes is a potent inducer of oxidative stress as evidenced by increased 8-OHdG 
immunolabeling and superoxide levels in WKY and SHR retina. 8-OHdG was further 
increased in diabetic SHR compared to diabetic WKY suggesting that hypertension has an 
additive effect on retinal oxidative damage in diabetes. These findings together with the 
elevated levels of Nox1, Nox2 and Nox4 transcripts in SHR retina indicate that Nox1/4 
inhibition might attenuate oxidative stress and retinal vascular pathology in diabetes. A 
limitation of our study is that we did not measure ROS and the protein levels of Nox isoforms 
early in diabetes and hypertension.31, 32 Nevertheless, our data that Nox1/4 inhibition 
markedly reduces oxidative stress in the retina, emphasise the potential of this treatment 
approach to attenuate the excess production of ROS that occurs in the retina in diabetes and 
hypertension.  
The BRB in the inner retina regulates the transport of fluids and proteins across 
endothelial cells, with tight junctional complexes having a key role in maintaining the 
integrity of the barrier.33 Further, macroglial Müller cells, whose processes are closely 
associated with the BRB, induce barrier properties in retinal endothelial cells.34, 35 Breakdown 
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of the BRB is highly influenced by VEGF produced by Müller cells which down-regulates 
the expression of tight junctional proteins such as occludin.36, 37 Our findings are consistent 
with our previous studies in diabetic rats demonstrating that retinal Müller cell gliosis and 
VEGF levels are increased as well as vascular leakage into the retina and vitreous, and that 
these events are exacerbated by systemic hypertension.38 We also identified that 
angiopoietin-2 levels are increased in retinas of diabetic WKY and SHR, which is of interest 
due to the ability of this factor to potentiate the actions of VEGF.39 Another indication that 
the integrity of the BRB was compromised in diabetic WKY and SHR was the reduced 
expression levels of ZO-1 and occludin which were further lowered by the combination of 
hypertension and diabetes.27 Importantly, Nox1/4 inhibition prevents the aforementioned 
damage to the retinal vasculature. These findings were confirmed in primary cultures of 
BREC, where the high glucose-induced increase in ROS and reduction in ZO-1 was 
ameliorated by GKT136901. Of interest is that Nox1/4 inhibition improved retinal pathology 
in SHR in the presence of elevated blood pressure. These data suggest that reducing excess 
ROS in the retina is a more important driver of diabetic and hypertensive retinopathy than 
lowering blood pressure. These findings might explain why angiotensin type 1 receptor 
blockade is only partially retinoprotective in patients with hypertension and DR.7, 8 
Nevertheless, we acknowledge that in our study, blood pressure in rats was not measured 
using radio-telemetry, a technique that could potentially reveal reductions in blood pressure 
following treatment with the Nox1/4 inhibitor. 
Evidence that Nox1, Nox2 and Nox4 isoforms have a causal role in various disorders 
has continued to expand, but far less understood is the role of Nox5 in disease including 
retinopathy.18 Since Nox5 is absent from the rodent genome, mouse models expressing the 
human Nox5 gene have been developed.40-42 In transgenic mice expressing Nox5 under the 
control of the Tie2 promoter, disruption of the blood-brain barrier due to stroke was increased 
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in transgenic Nox5 mice, indicating a critical role for Nox5 in vascular integrity in the central 
nervous system.40 Our findings in OIR are in agreement, with Nox5 overexpression in the 
vasculature, exacerbating breakdown of the BRB as reflected by increased vascular leakage 
and VEGF expression. Neovascularization within the inner retina and into the vitreous is a 
hallmark feature of end-stage proliferative DR,2 however, this vascular pathology does not 
develop in diabetic rodents. OIR re-capitulates the neovascularization that occurs in 
retinopathy of prematurity in children,43 and has similarities to proliferative DR. It has been 
reported that knockdown of Nox4 by adenovirus delivered siRNA reduced retinal 
neovascularization in OIR,44 and Nox1/4 inhibition attenuated retinal neovascularization and 
VEGF levels in this model.15 We present novel in vivo evidence that overexpression of Nox5 
in endothelial cells exacerbates retinal neovascularization in OIR. These data support 
previous in vitro studies showing that overexpression of Nox5 enhances endothelial cell 
proliferation and tubule formation.16 
To evaluate the therapeutic potential of our findings we utilized BREC which we 
reported express Nox5 as well as Nox1, Nox2 and Nox4.15 Here, we identified that the 
mRNA levels of these Nox isoforms except for Nox2 are increased by high glucose in BREC. 
These findings are somewhat different from our data in rats where Nox2 mRNA levels in 
whole retina were increased with diabetes. The reasons for these differences are unclear but 
might indicate that Nox expression levels in whole retina do not necessarily reflect 
expression levels in individual cell populations such as endothelial cells. The ability of Nox5 
siRNA as well as Nox1/4 inhibition to attenuate the high glucose-induced up-regulation of 
ROS and VEGF in BREC highlights the vasculo-protective effects of reducing Nox5 as well 
as Nox1 and Nox4 in diabetes. A limitation of our study was that Nox5 siRNA did not 
completely reduce Nox5 mRNA and protein levels, with a greater suppression of Nox5 
potentially eliciting further reductions in ROS. 
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Inflammation contributes to endothelial cell injury in the retina with ICAM-1 
influencing leukocyte adhesion.28 Our data emphasize the capacity of Nox1/4 inhibition to 
attenuate the up-regulation of ICAM-1 in the retina caused by diabetes and exacerbated by 
hypertension. We determined that the high glucose-mediated increase in endothelial cell 
derived ICAM-1 is particularly responsive to Nox1/4 inhibition as well as to down-regulation 
of Nox5.  These findings highlight the importance of reducing the expression of certain Nox 
isoforms in DR. The inflammatory mediators, TNFα and MCP-1, are produced by various 
cell types within the retina45, 46 and influence the endothelial cell dysfunction that occurs in 
response to diabetes and hypertension. Indeed, these factors not only stimulate the adherence 
of leukocytes to the vasculature, but also facilitate breakdown of the BRB in DR.28, 47 The 
ability of Nox1/4 inhibition to attenuate the up-regulation of TNFα and MCP-1 in the retina 
of diabetic WKY and SHR adds support to evidence that Nox1/4 inhibition has potent anti-
inflammatory actions in retinopathy48 and other settings such as diabetes-associated 
atherosclerosis and nephropathy.23, 49, 50 
 
Perspectives 
Targeting Nox isoforms is a potential treatment for DR. We demonstrated that Nox1/4 
inhibition protects the BRB in diabetes and in the common clinical scenario when 
hypertension is superimposed. The role of Nox5 in retinopathy has been difficult to study due 
to its absence from the rodent genome. We provide new evidence that Nox5 is involved in 
retinal vasculopathy. Collectively, these findings provide a rationale for investigating Nox5 
inhibitors alongside Nox1/4 inhibition as a new treatment approach for DR.  
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29. Dosso AA, Leuenberger PM, Rungger–Brändle E. Remodeling of retinal capillaries in 
the diabetic hypertensive rat. Invest Ophthalmol Vis Sci. 1999;40:2405-2410 
30. Silva KC, Rosales MAB, Biswas SK, Lopes de Faria JB, Lopes de Faria JM. Diabetic 
retinal neurodegeneration is associated with mitochondrial oxidative stress and is 
improved by an angiotensin receptor blocker in a model combining hypertension and 
diabetes. Diabetes. 2009;58:1382-1390 
31. Miller WP, Toro AL, Barber AJ, Dennis MD. REDD1 Activates a ROS-generating 
feedback loop in the retina of diabetic mice. Invest Ophthalmol Vis Sci. 
2019;60:2369-2379 
32. Carpi-Santos R, Ferreira MJ, Pereira Netto AD, Giestal-de-Araujo E, Ventura AL, 
Cossenza M, Calaza KC. Early changes in system xc
_ and glutathione in the retina of 
diabetic rats. Exp Eye Res. 2016;146:35-42 
33. Diaz-Coranguez M, Ramos C, Antonetti DA. The inner blood-retinal barrier: Cellular 
basis and development. Vision Res. 2017;139:123-137 
34. Tout S, Chan-Ling T, Hollander H, Stone J. The role of Muller cells in the formation 
of the blood-retinal barrier. Neuroscience. 1993;55:291-301 
35. Coughlin BA, Feenstra DJ, Mohr S. Muller cells and diabetic retinopathy. Vision Res. 
2017;139:93-100 
 19 
36. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K, Feener EP, Aiello LP. 
Cyclic stretch and hypertension induce retinal expression of vascular endothelial 
growth factor and vascular endothelial growth factor receptor-2. Diabetes. 
2001;50:444 
37. Chan WY, Cheng RSY, Yew DT. Postnatal changes of vascular endothelial growth 
factor (VEGF) expression in the retinae of normal and hypertensive rats. Life Sci. 
2000;66:1615-1625 
38. Alrashdi SF, Deliyanti D, Wilkinson-Berka JL. Intravitreal administration of 
endothelin type A receptor or endothelin type B receptor antagonists attenuates 
hypertensive and diabetic retinopathy in rats. Exp Eye Res. 2018;176:1-9 
39. Rangasamy S, Srinivasan R, Maestas J, McGuire PG, Das A. A potential role for 
angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. 
Invest Ophthalmol Vis Sci. 2011;52:3784-3791 
40. Casas AI, Kleikers PWM, Geuss E, Langhauser F, Adler T, Busch DH, Gailus-Durner 
V, de Angelis MH, Egea J, Lopez MG, Kleinschnitz C, Schmidt HHHW. Calcium-
dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in 
stroke.  J Clin Invest. 2019;129:1772-1778 
41. Jha JC, Dai A, Holterman CE, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm 
KAM. Endothelial or vascular smooth muscle cell-specific expression of human 
NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. 
Diabetologia. 2019 
42. Holterman CE, Boisvert NC, Thibodeau JF, Kamto E, Novakovic M, Abd-Elrahman 
KS, Ferguson SSG, Kennedy CRJ. Podocyte NADPH oxidase 5 promotes renal 
inflammation regulated by the Toll-Like receptor pathway. Antioxid Redox Signal. 
2019;30:1817-1830 
 20 
43. Sapieha P, Joyal JS, Rivera JC, Kermorvant-Duchemin E, Sennlaub F, Hardy P, 
Lachapelle P, Chemtob S. Retinopathy of prematurity: understanding ischemic retinal 
vasculopathies at an extreme of life. J Clin Invest. 2010;120:3022-3032 
44. Li J, Wang JJ, Zhang SX. NADPH oxidase 4-derived H2O2 promotes aberrant retinal 
neovascularization via activation of VEGF receptor 2 pathway in oxygen-induced 
retinopathy. J Diabetes Res. 2015;2015:963289 
45. Dong N, Li X, Xiao L, Yu W, Wang B, Chu L. Upregulation of retinal neuronal 
MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. Invest 
Ophthalmol Vis Sci. 2012;53:7567-7575 
46. Deliyanti D, Alrashdi SF, Tan SM, Meyer C, Ward KW, de Haan JB, Wilkinson-
Berka JL. Nrf2 activation Is a potential therapeutic approach to attenuate diabetic 
retinopathy. Invest Ophthalmol Vis Sci. 2018;59:815-825 
47. Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ, Vinores SA. TNFalpha is 
required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents 
leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis 
Sci. 2011;52:1336-1344 
48. Deliyanti D, Wilkinson-Berka JL. Inhibition of NOX1/4 with GKT137831: a 
potential novel treatment to attenuate neuroglial cell inflammation in the retina. J 
Neuroinflammation. 2015;12:136 
49. Di Marco E, Gray SP, Chew P, Koulis C, Ziegler A, Szyndralewiez C, Touyz RM, 
Schmidt HH, Cooper ME, Slattery R, Jandeleit-Dahm KA. Pharmacological 
inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-
inflammatory responses in diabetic Apoe(-/-) mice. Diabetologia. 2014;57:633-642 
50. Gorin Y, Cavaglieri RC, Khazim K, Lee DY, Bruno F, Thakur S, Fanti P, 
Szyndralewiez C, Barnes JL, Block K, Abboud HE. Targeting NADPH oxidase with 
 21 
a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J 
Physiol Renal Physiol. 2015;308:F1276-1287 
 
Novelty and Significance 
 
What is New 
 Nox1/4 inhibition protects the blood-retinal barrier and reduces oxidative stress and 
inflammation induced by diabetes and hypertension. 
 Nox5 promotes retinal neovascularization and vascular permeability.  
 
What is Relevant 
Inhibition of Nox1/4 as well as Nox5 may offer a unique approach to preventing damage to 
the retinal microvasculature. 
 
Summary 
Oxidative stress threatens the BRB, with Nox1, Nox4 and Nox5 having a causal role. 
Strategies to inhibit these Nox isoforms may be more efficacious than targeting single Nox 
isoforms and thereby prevent the progression to vision loss in diabetes and hypertension. 
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Figure 1. Oxidative stress in DR is exacerbated in SHR and reduced by Nox1/4 
inhibition. 
NDB, non-diabetic. DB, diabetic. GKT, GKT136901. GCL, ganglion cell layer. IPL, inner 
plexiform layer. INL, inner nuclear layer. ONL, outer nuclear layer. RLU, relative 
luminescence unit. (A) Nox1, (B) Nox2 and (C) Nox4 mRNA levels in retina. n=5-9 rats per 
group. (D) Representative images showing 8-OHdG immunolabeling in 3μm paraffin 
sections. Counterstain, haematoxylin. 8-OHdG in non-diabetic WKY is minimal. 8-OHdG in 
the GCL (arrows) and INL is increased in non-diabetic SHR, and further increased in diabetic 
WKY and SHR in these locations as well as Müller cell processes (arrowheads). GKT136901 
reduced 8-OHdG immunolabeling in diabetic rats. Scale bar, 40μm. (E) 8-OHdG 
quantitation. n=5-6 rats per group. (F) Superoxide levels in retina are unchanged with 
hypertension but increased with diabetes in WKY and SHR. GKT136901 reduced superoxide 
levels in retina of diabetic rats. n=4-6 rats per group. *P<0.05, **P<0.01, ***P<0.001. 
MeanSD. 
 
Figure 2. Diabetes-induced retinal vascular permeability is exacerbated in SHR and 
reduced by Nox1/4 inhibition. 
NDB, non-diabetic. DB, diabetic. GKT, GKT136901. Vascular leakage measured by ELISA 
for albumin in (A) retina and (B) vitreous. n=5-8 rats per group. VEGF (C) mRNA and (D) 
protein levels in retina. (E) VEGF protein levels in vitreous and (F) angiopoietin-2 (Ang2) 
mRNA levels in retina. n=5-9 rats per group. *P<0.05, **P<0.01, ***P<0.001. MeanSD.  
 
Figure 3. Diabetes-induced retinal gliosis and inflammation are exacerbated in SHR 
and reduced by Nox1/4 inhibition. 
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NDB, non-diabetic. DB, diabetic. GKT, GKT136901. ILM, inner limiting membrane. GCL, 
ganglion cell layer. IPL, inner plexiform layer. INL, inner nuclear layer. ONL, outer nuclear 
layer. (A) Representative images showing GFAP immunolabeling in 3μm paraffin sections. 
GFAP in non-diabetic WKY is restricted to the retinal surface at the ILM (asterisk) adjacent 
to the vitreous. GFAP is present in Müller cell processes (arrowheads) in non-diabetic SHR 
and increased with diabetes in WKY and SHR. GKT136901 reduced GFAP in diabetic rats. 
Scale bar, 40μm. (B) GFAP quantitation. n=5 rats per group. (C) ICAM-1 and (D) TNFα 
mRNA levels in retina. MCP-1 protein levels in retina (E) and vitreous (F). n=5-9 rats per 
group. *P<0.05, **P<0.01, ***P<0.001. MeanSD. 
 
Figure 4. Nox1/4 inhibition reduced high glucose-induced damage to retinal endothelial 
cells in vitro. 
NG, normal glucose. HG, high glucose. GKT, GKT136901. Experiments were performed in 
primary cultures of bovine retinal endothelial cells. (A) Nox isoform mRNA levels. (B) Mean 
fluorescent intensity (MFI) for dihydroethidium (DHE) to detect ROS by flow cytometry. (C) 
Western blots for ZO-1. (D) VEGF and (E) ICAM-1 mRNA levels. n=6-12 samples from 2 
to 3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001. MeanSD. 
 
Figure 5. Nox5 inhibition reduced high glucose-induced angiogenic factors and 
inflammation in retinal endothelial cells in vitro.  
NG, normal glucose. HG, high glucose. Experiments were performed in primary cultures of 
bovine retinal endothelial cells. (A) Mean fluorescent intensity (MFI) for dihydroethidium 
(DHE) to detect ROS by flow cytometry. (B) si-Nox5 reduced high glucose-induced ROS 
levels. (C) VEGF protein levels in supernatants. (D) VEGF and (E) ICAM-1 mRNA levels. 
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*P<0.05, **P<0.01, ***P<0.001. n=9-12 samples from 3 independent experiments. 
MeanSD. 
 
Figure 6. Nox5 exacerbates retinal neovascularization and inflammation in OIR.   
NV, neovascularization. Relative luminescence unit, RLU. (A) Representative flat-mounts of 
retinas from mice with oxygen-induced retinopathy (OIR) stained with FITC-conjugated 
isolectin B4 to identify the vasculature at postnatal day 18. Upper panel shows the entire 
retina. Yellow boxes in the upper panel are shown in higher magnification in the lower panel. 
Arrowheads show areas of NV. Scale bar=0.125mm. (B) Transgenic mice expressing Nox5 
in endothelial cells (Ve-Cad+Nox5+) developed more extensive retinal NV than OIR 
littermate controls. (C) Retinal vascular leakage measured by albumin ELISA. (D) VEGF 
protein, (E) VEGF mRNA and (F) ICAM-1 mRNA levels are increased in retinas of Ve-
Cad+Nox5+ OIR mice. *P<0.05, **P<0.01, ***P<0.001. n=6-9 mice per group. MeanSD.  
 
